--- title: "Polyrizon (PLRZ) news: offering" url: "https://aibio.space/companies/polyrizon/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PLRZ offering news: Polyrizon closes $4.0 million registered direct offering and private placement at $12.00. Polyrizon Ltd. (NASDAQ: PLRZ), Israel." --- PLRZ Polyrizon Ltd. NASDAQ · Israel # Polyrizon (PLRZ) news PLRZ offering news Listings · 2026-09-28 ## [Polyrizon reports $8,410 thousand in cash at June 30, 2026](https://aibio.space/news/polyrizon-reports-8-410-thousand-cash-june-30-2026/) Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months. ## Latest Polyrizon news 1. 2026-09-04 Financings [Polyrizon closes $4.0 million registered direct offering and private placement at $12.00](https://aibio.space/news/polyrizon-closes-4-0-million-registered-direct-offering-private/) Polyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion. 2. 2025-12-05 Listings [Polyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering](https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/) Expected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price. ## Polyrizon at a glance - **Ticker**: PLRZ - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $1.3 million ### Related companies - [Chemomab Therapeutics](https://aibio.space/companies/chemomab-therapeutics/) NASDAQ: CMMB - [Matricelf](https://aibio.space/companies/matricelf/) TASE: MTLF - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) TASE: NRGN - [Pluri](https://aibio.space/companies/pluri/) NASDAQ: PLUR - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) AMEX: RGNT - [Enlivex](https://aibio.space/companies/enlivex/) NASDAQ: ENLV - [Evogene](https://aibio.space/companies/evogene/) NASDAQ: EVGN ### Also on NASDAQ - [ICON](https://aibio.space/companies/icon/) ICLR - [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) MIRA - [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) GLUE - [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI - [SS Innovations International](https://aibio.space/companies/ss-innovations-international/) SSII - [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA ## Polyrizon annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | [$534,000](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | | Net income (loss) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | [-$1.5 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | | Cash from operations | [-$4.5 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | [-$1.1 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | | Cash and equivalents | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | [$2.6 million](https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Polyrizon Has Polyrizon raised money recently? Our latest story on this, dated Sep 4, 2026: "Polyrizon closes $4.0 million registered direct offering and private placement at $12.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polyrizon-closes-4-0-million-registered-direct-offering-private/). What is the ticker symbol of Polyrizon? Polyrizon Ltd. trades under the ticker PLRZ on NASDAQ. Where is Polyrizon listed? Polyrizon Ltd. is listed on NASDAQ. What is the SEC CIK of Polyrizon? The SEC Central Index Key (CIK) for Polyrizon Ltd. is 1893645. Its filings are on SEC EDGAR. How many shares does Polyrizon have outstanding? 1,608,266 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-25. Which country or territory is Polyrizon listed under? Our directory records Polyrizon Ltd. under Israel. What does Polyrizon do? Our directory classifies Polyrizon Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Polyrizon? The ISIN recorded for Polyrizon Ltd. is IL0011814113. Does aibio.space cover Polyrizon? aibio.space lists Polyrizon Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Polyrizon incorporated? SEC records list its state or country of incorporation as L3. Is Polyrizon profitable? Polyrizon Ltd. reported a net loss of $3.3 million for the fiscal year ended Dec 31, 2025, and used $4.5 million of cash in operations, per its annual report to the SEC. How much does Polyrizon spend on research and development? $2.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Polyrizon have? $1.3 million in cash at Dec 31, 2025, per its 20-F. What is the latest Polyrizon (PLRZ) stock news? Our latest story on Polyrizon, dated Sep 28, 2026: "Polyrizon reports $8,410 thousand in cash at June 30, 2026". Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months. [Source](https://aibio.space/news/polyrizon-reports-8-410-thousand-cash-june-30-2026/). Is Polyrizon at risk of delisting? Our latest listing story, dated Sep 28, 2026: "Polyrizon reports $8,410 thousand in cash at June 30, 2026". Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months. [Source](https://aibio.space/news/polyrizon-reports-8-410-thousand-cash-june-30-2026/). ## Investor discussion: Polyrizon Members talk about Polyrizon (PLRZ). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Polyrizon, newest first. Each line links the filing it comes from. 1. 2026-09-28 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026104045/ea030456801ex99-1.htm) 2. 2026-09-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026097441/ea0302348-424b5_polyrizon.htm) 3. 2026-09-04 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026097444/ea030232201ex99-1.htm) 4. 2026-04-08 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026041507/ea0285368-424b5_polyrizon.htm) 5. 2026-04-08 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026041508/ea028536701ex99-1.htm) 6. 2026-02-04 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390026011807/ea027553902ex99-1_polyrizon.htm) 7. 2025-12-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025118451/ea0268528-424b5_polyrizon.htm) 8. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025118454/ea0268528-6k_polyrizon.htm) 9. 2025-11-25 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025114396/ea0266911-6k_polyrizon.htm) 10. 2025-09-17 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025088569/ea025666601ex99-1_polyrizon.htm) 11. 2025-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025076089/ea025325902ex99-1_polyrizon.htm) 12. 2025-07-31 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025069999/ea025106301ex99-1_polyrizon.htm) 13. 2025-07-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025063936/ea024899202ex99-1_polyrizon.htm) 14. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025047370/ea024329101ex99-1_polyrizon.htm) 15. 2025-05-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025046620/ea0243080-6k_polyrizon.htm) 16. 2025-05-01 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025038043/ea0240173-6k_polyrizon.htm) 17. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025031097/ea023780601ex99-1_polyrizon.htm) 18. 2025-04-01 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025027163/ea023642501ex99-1_poly.htm) 19. 2025-03-13 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025023737/ea023433301ex99-1_polyrizon.htm) 20. 2025-03-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1893645/000121390025022732/ea0232371-20f_polyrizon.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PLRZ on TradingView](https://www.tradingview.com/symbols/NASDAQ-PLRZ/). ## SEC filings and registration - **SEC name**: Polyrizon Ltd. - **CIK**: 1893645 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: PLRZ (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: HAPNINA ST 8, RA'ANANA, 4321545 - **Phone**: 972-54-7979668 - **Shares outstanding**: 1,608,266 as of 2025-12-31 (20-F filed 2026-03-25) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026106814/ea0307687-6k_polyrizon.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026104045/ea0304568-6k_polyrizon.htm) filed 2026-09-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026097696/ea0304686-6k_polyrizon.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026097444/ea0302322-6k_polyrizon.htm) filed 2026-09-04 - [424B5](https://www.sec.gov/Archives/edgar/data/1893645/000121390026097441/ea0302348-424b5_polyrizon.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026092083/ea0302853-6k_polyrizon.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026077540/ea0297808-6k_polyrizon.htm) filed 2026-07-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1893645/000121390026074946/ea0296863-6k_polyrizon.htm) filed 2026-07-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001893645), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Polyrizon Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PLRZ, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Polyrizon Ltd. - **Ticker**: PLRZ - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Biotechnology - **ISIN**: IL0011814113 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PLRZ/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/polyrizon/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Polyrizon (PLRZ) news: offering", 2026-10-31, https://aibio.space/companies/polyrizon/